Related news from
Fri, 25 Sep 2026 12:00:00 +0000	Cencora Elects Robert E. Sanchez to Its Board of Directors CONSHOHOCKEN, Pa., September 25, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.
Mon, 21 Sep 2026 23:02:08 +0000	Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027 Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses. Speaking at the Morgan Stanley Global Heal
Mon, 21 Sep 2026 10:02:04 +0000	Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi
Sat, 19 Sep 2026 12:38:37 +0000	Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch? On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion […]
Wed, 16 Sep 2026 19:58:00 +0000	Cencora Tech Chief: AI Is Cutting Some Medical Treatment Decisions in Half Cencora Global Chief Data and Information Officer Pawan Verma spoke with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit about how AI is being used in healthcare to speed access to treatment. Verma described a retinal oncology use case in which doctors analyze large volumes of imaging data to determine treatment, saying AI is helping cut a decision process that can take 30 to 90 days roughly in half.
Tue, 15 Sep 2026 14:29:00 +0000	The Realities of Managing Enterprise AI A panel of CIOs from Indeed, New York Life and Cencora discuss the risks and advantages of enterprise AI, including operational efficiency, financial waste and the need to implement “control towers” for human oversight of consequential decisions.
Thu, 24 Sep 2026 20:22:01 +0000	AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.
Mon, 14 Sep 2026 13:00:00 +0000	Coultreon Biopharma Appoints Nate Massari as Chief Business Officer Nate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. September 14, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Nate Massari as Chief Business Officer. Nate brings more than 25 years of expe
Mon, 28 Sep 2026 13:18:36 +0000	1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Fri, 25 Sep 2026 21:22:01 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
Tue, 22 Sep 2026 13:32:00 +0000	Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery? CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.
Sun, 20 Sep 2026 14:08:24 +0000	Cencora (COR) Lifts EPS Outlook And Buyback, Is The Stock Still Below Fair Value? Cencora (COR) just combined a stronger fiscal third quarter, a higher full year adjusted EPS outlook, and a US$1b buyback with plans to brief investors at two New York healthcare conferences. Despite the upbeat earnings message, Cencora’s share price has eased in the short term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78. At the same time, a 90 day share price return of 13.82% and a 1 year total shareholder return of 7.28% sit...
Mon, 14 Sep 2026 15:00:55 +0000	AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
Mon, 14 Sep 2026 11:03:45 +0000	Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
Fri, 11 Sep 2026 18:21:00 +0000	CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue? Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
Fri, 11 Sep 2026 15:49:37 +0000	Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
Fri, 11 Sep 2026 15:29:27 +0000	Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
Thu, 10 Sep 2026 17:46:13 +0000	AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
Thu, 10 Sep 2026 17:45:04 +0000	2 S&P 500 Stocks with Exciting Potential and 1 We Question The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Thu, 24 Sep 2026 21:19:01 +0000	AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!